Drug Profile
Basiliximab biobetter - Sinomab/Sorrento
Alternative Names: CMAB-006; STI-003Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Mabtech
- Developer Sinomab
- Class Biobetters; Monoclonal antibodies
- Mechanism of Action Interleukin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders